Rare Disease Specialist Ultragenyx Takes $45MM Series A Round
This article was originally published in The Pink Sheet Daily
Executive Summary
Led by a BioMarin veteran, the year-old startup has already licensed five compounds, and is preparing to take one into the clinic.
You may also be interested in...
Ultragenyx Plans Five Clinical Trials For 2014
The rare disease biotech is confident it can move all of its programs forward and has no interest in selling its commercialization rights to a Big Pharma partner.
Ultragenyx Takes On Rare Childhood Disease With In-licensing Deal
Rare disease company Ultragenyx has in-licensed the North American rights to a treatment for fatty-acid oxidation disorder, adding its third clinical-stage drug to its ultra-rare disease pipeline.
Ultragenyx Raises $75 Million Series B, Prepares For A 2014 IPO
Ultragenyx raised $75 million in a Series B financing led by Adage Capital Partners. The funding will support the biotech’s two lead programs that are meant to treat ultra-rare genetic disorders and will position the company for an initial public offering.